Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4 different tests: molecular, radiological, and blood based. It will be performed on 240 prospectively-collected samples. A score of 0-4 will[…]
An inhaled vaccine could be used for mesothelioma treatment soon. Research done at MIT is showing that the inhaled vaccine can trigger an immune response for certain infections and possibly lung-based cancers. This is great news for people with mesothelioma. Lung infections typically start on mucosal membranes, so researchers created[…]
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
A Phase III Clinical Trial is Looking at the Combination of Durvalumab and Chemotherapy to Treat Mesothelioma
A new clinical trial involving durvalumab should be closely monitored by the Food and Drug Administration. The phase III clinical trial is being performed in Baltimore, Cleveland, and Ann Arbor as well as places in New Zealand and Australia. The randomized trial is known as DREAM3R. It wants to figure[…]
Oncologists in Japan have found a way to determine which patients would best benefit from second-line chemotherapy. Second-line treatment is a second treatment that doctors perform after trying another treatment first. When the first treatment doesn’t work or stops working, a second-line treatment is tried to see if it will[…]
Surgery can be hard on the body, but it can help some mesothelioma patients if done a second time. People could still have a good quality of life and even an extended survival if they undergo the aggressive surgery. This surgery is not common and would not be recommended for[…]
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
The purpose of the Dielectrics Properties of Thoracic Malignancies Study (DPTMS) is to provide a wealth of knowledge for investigators involved in establishing a new and effective treatment for a variety of solid tumors using tumor treatment fields. It is intended to provide biospecimen (tumor/healthy) together with demographic data (age, sex, race, occupational history, and other epidemiologic information), and clinical data (stage, treatment, survival information, and annotated CT’s). Our specific aims are to test the following hypotheses: 1) Electric properties of thoracic tumors differ from electric properties of surrounding healthy tissue 2) Different tumor types will have different electric properties 3) Electric properties of individual tumors are heterogeneous 4) Electric properties of tumors are related to the structure and composition of the underlying tissue 5) Use of standard medical imaging data (CT) will permit mapping of electric properties.
Mesothelioma is not found in as many women as men, but studies show that women can survive longer than men. Researchers at the International Mesothelioma Program at Brigham and Women’s Hospital in Boston found that a gene can help predict the prognosis and treatment outcome for women patients with mesothelioma.[…]
Primary Outcome Measures Prevalence of germline BAP1 variants in the unselected general population of cancer patients [ Time Frame: 5 years ] Clinical phenotypes (this includes premalignant lesions, tumor type and age of onset) in at risk blood-line family members of the patients [ Time Frame: 5 years ] Secondary Outcome Measures Environmental risk factors modifying cancer risk[…]
There is promising new data from the makers of ONCOS-102 that shows that the treatment can help improve the long-term survival of mesothelioma patients. ONCOS-102 was recently given Fast-Track approval by the FDA to speed up its development. ONCOS-102 is a modified adenovirus that infects cancer cells. The new mesothelioma[…]